A cystic fibrosis monopoly generating 40.3% operating margins trades at reasonable multiples despite management burning $1B on buybacks at $868 versus today's $439.
This framework sees a pharmaceutical monopoly with fortress economics trading at a reasonable price, despite management's costly buyback missteps.
Does this business have a durable competitive advantage?
This framework recognizes a textbook monopoly — one drug treating one disease with no alternatives. The 40% operating margins and inflation-linked pricing power demonstrate exactly the kind of toll-bridge economics Buffett cherishes. When patients need your product to breathe, competitive dynamics become irrelevant.
How predictable are this company's earnings?
Applying this lens reveals a metronome — 36 out of 39 quarters with positive surprises approaches the predictability of a utility company. The framework values businesses where next quarter's earnings can be estimated with a pencil, not a computer model.
How much cash does an owner really get to keep?
This framework sees a cash-generating machine where accounting understates economic reality. When a business needs just 4.6% of revenue for maintenance capex while generating 40% operating margins, owners keep most of what the income statement promises.
If you bought this entire business today, would the earnings justify the price?
The framework finds the math acceptable but uninspiring — paying 24 times earnings for a business growing at 9% works if the moat endures. At the 40th percentile of its historical P/E range, this isn't expensive for what you get, just fairly priced.
Are managers acting like owners or agents?
This lens reveals troubling capital allocation — buying high while insiders sell suggests managers who excel at science but fail at finance. The framework sees the $1B destruction of shareholder value through poorly timed buybacks as a red flag on an otherwise strong business.
Applying this framework reveals a paradox: a monopoly business with predictable earnings and widening moat, undermined by management's capital allocation mistakes. The $2 billion in underwater buybacks represents money that could have funded research or been returned when shares were cheaper. Still, when you own the only drug that helps 100,000 people breathe normally, temporary management missteps rarely prove fatal. Would a rational owner sell this toll bridge because the toll collector overpaid for his own shares?
This analysis applies Warren Buffett's published investment framework to publicly available financial data. It is not authored by, endorsed by, or affiliated with Warren Buffett. Educational purposes only. Not financial advice.